Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
My previous session
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 09/21 10:26:03 am
76.215 EUR   +0.52%
09/20BAYER : Compugen earns $7.8m payment from Bayer
AQ
09/20BAYER : Levels Sights On Weedkiller Verdict
DJ
09/19BAYER : Steps Up Fight Over Weed Killer Blamed for Cancer - Update
DJ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Sector news Pharmaceuticals - NEC
08:15aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/20Animal health firm Elanco surges 41 percent on debut
RE
09/20WALL STREET STOCK EXCHANGE : Aurora Cannabis plans U.S. stock listing in October
RE
09/20ELI LILLY AND : Lilly Spinoff Elanco Animal Health Surges Early in Market Debut ..
DJ
09/20ONCOMED PHARMACEUTICALS : Says Celgene Won't Exercise Option to License Navicixi..
DJ
09/20PFIZER : 20vPnC Vaccine Gets FDA Breakthrough-Therapy Designation
DJ
09/20Nestle aims to shed skin unit to focus on food, nutrition
RE
09/20Nestle aims to shed skin unit to focus on food, nutrition
RE
09/20EU approves fifth copy of AbbVie's $18 billion drug Humira
RE
09/20SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/19ELI LILLY AND : IPO of Lilly Unit Elanco Animal Health Prices Above Range at $24
DJ
09/19COCA COLA : moving ahead with takeover of Nigeria's Chi juice
RE
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/19SHIRE : Rule 2.9 Announcement
DJ
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/18ABBVIE : California Insurance Commissioner Sues AbbVie, Alleging 'Kickbacks' for..
DJ
09/18COCA COLA : buys Australia's kombucha maker Mojo
RE
09/18GLAXOSMITHKLINE : GSK grabs new drug development head from Boehringer
RE
09/18Aurora Cannabis Says No Current Deal on Partnership With Beverage Company
DJ
09/18COCA COLA : Aurora says no deal with beverage makers for weed-based drinks
RE
09/18NOVO NORDISK A/S : Cuts 400 Jobs From R&D to Focus on New Pipeline
DJ
09/18NOVO NORDISK A/S : lays off 400 staff in research & development unit
RE
09/18Exclusive - India, U.S. closing in on package deal to remove trade irritants
RE
09/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/17NOVARTIS : links bonuses to ethics in bid to rebuild reputation
RE
09/17ASTRAZENECA : Three-Drug Combination Meets 8 out of 9 Objectives in COPD Trial
DJ
09/17SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/15TEVA PHARMACEUTICAL INDUSTRIES : FDA Approves Teva's Migraine Drug Ajovy -- Upda..
DJ
09/14TEVA PHARMACEUTICAL INDUSTRIES : FDA Approves Teva's Migraine Drug Ajovy
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/14Allergan says revenue from aesthetics unit may double by 2025
RE
09/14NOVO NORDISK A/S : Expects U.S. Drug Price Hikes to Get Tougher
DJ
09/14SUN PHARMACEUTICAL INDUSTRIES : Pharma Gets FDA Approval for Eye Drug Xelpros
DJ
09/14GlaxoSmithKline's ViiV Submits Marketing Application to EMA for HIV Treatment
DJ
09/14Takeda gets China's approval for $62 billion Shire purchase
RE
09/14ASTRAZENECA : FDA Approves Lumoxiti for Hairy Cell Leukemia
DJ
09/14SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
09/13Roche Works to Fill Sales Gap as Biosimilars Emerge -Reuters
DJ
09/13ASTRAZENECA : FDA Approves New Kind of Treatment for Rare Blood Cancer Known as ..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13Smiths and ICU Medical healthcare merger talks collapse
RE
09/13ROCHE : boss says Brexit and curbs on drug use pose threat to UK science
RE
09/13BAYER : pharma unit head Weinand quits to join Sanofi
RE
09/13Sanofi Poaches Bayer Manager to Lead New Primary Care Unit
DJ
09/13South Africa's Aspen sells infant formula business to Lactalis for $865 milli..
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 39 117 M
EBIT 2018 7 261 M
Net income 2018 4 895 M
Debt 2018 39 658 M
Yield 2018 3,74%
P/E ratio 2018 14,96
P/E ratio 2019 13,99
EV / Sales 2018 2,82x
EV / Sales 2019 2,26x
Capitalization 70 706 M
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
BAYER-25.92%83 311
JOHNSON & JOHNSON0.53%376 820
PFIZER19.44%253 595
NOVARTIS-0.56%216 184
ROCHE HOLDING LTD.-4.65%211 637
MERCK AND COMPANY25.79%186 114
AMGEN17.99%131 526
ABBOTT LABORATORIES20.03%120 171
ELI LILLY AND COMPANY25.20%113 563
SANOFI3.92%109 834
BRISTOL-MYERS SQUIBB COMPANY-0.78%99 218
GLAXOSMITHKLINE12.35%97 628
ASTRAZENECA8.81%93 281
NOVO NORDISK A/S-10.76%89 874
ALLERGAN PLC14.95%63 826
CELGENE CORPORATION-15.39%61 460
SHIRE15.62%54 502
ASTELLAS PHARMA INC38.66%35 399
CHUGAI PHARMACEUTICAL CO LTD21.84%34 812
TAKEDA PHARMACEUTICAL CO LTD-27.49%33 184
JIANGSU HENGRUI MEDICINE CO LTD11.55%31 799